Price movement over the last 24 hours
ARK Fintech Innovation ETF vs ARK Genomic Revolution ETF — how do they compare? ARK Fintech Innovation ETF trades at $41.45, while ARK Genomic Revolution ETF trades at $40.95. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | ARKG | |
|---|---|---|
Sector | Sector/Thematic | Sector/Thematic |
52-Week High | $58.82 | $43.57 |
52-Week Low | $36.14 | $23.09 |
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $41.63, up 0.43% with bullish technical signals from moving averages and strong trend strength (ADX 39.69). The stock faces resistance at $42 with support at $41. Recent coverage highlights institutional interest in Cathie Wood's and Bill Ackman's overlapping investments in Magnificent Seven stocks.
The ETF's outlook is supported by technical momentum but lacks fundamental financial data disclosure. Key risks include market volatility and dependency on top holdings performance. Institutional overlap suggests confidence in selected growth stocks, though valuation metrics remain undisclosed.
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Trailing returns across standard periods
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →